Novartis' Zometa Adds Warning On Renal Safety
This article was originally published in The Pink Sheet Daily
Executive Summary
Revised labeling recommends dosing should be decreased for patients with mild-to-moderate renal impairment, based on the patient's creatinine clearance levels. Novartis recommends identification and management of "factors predisposing of renal deterioration."